Fresenius Kabi Caring For Life
For US and Puerto Rico Healthcare Professionals
For US and Puerto Rico Healthcare Professionals

Kabiven helps dietitiansSimplify calculations

Kabiven helps you meet A.S.P.E.N. recommendations for nutrient needs1,2

Chart showing A.S.P.E.N. recommendations for nutrient needs
*A.S.P.E.N. Parenteral Nutrition Handbook, 2014,3 A.S.P.E.N. Adult Nutrition Support Core Curriculum, 2012.4

Kabiven helps customize PN therapy with a range of volumes and compositions

Volume (mL) 1026 1540 2053 2566
Amino Acids (g) 34 51 68 85
Nitrogen (g) 5.4 8.2 10.9 13.6
Dextrose (g) 100 150 200 250
Lipids (g) 40 60 80 100
Total kcal 870 1310 1745 2180
Volume (mL) 1026 1540 2053 2566
Sodium (mEq) 32 48 64 80
Potassium (mEq) 24 35 47 59
Magnesium (mEq) 8 12 16 20
Acetate (mEq) 39 59 78 98
Chloride (mEq) 46 69 92 115
Sulfate (mEq) 8 12 16 20
Calcium (mEq) 4 6 8 10
Phosphorus (mmol) 10 15 20 25
Osmolarity (mOsm/L) 1060 1060 1060 1060
Volume (mL) 1440 1920 2400
Amino acids (g) 34 45 57
Nitrogen (g) 5.4 7.2 9.1
Dextrose (g) 97 130 162
Lipids (g) 51 68 85
Total kcal 970 1300 1620
Volume (mL) 1440 1920 2400
Sodium (mEq) 32 42 53
Potassium (mEq) 24 33 41
Magnesium (mEq) 8 11 13
Acetate (mEq) 39 52 65
Chloride (mEq) 46 61 77
Sulfate (mEq) 8 11 13
Calcium (mEq) 4 5 7
Phosphorus (mmol) 11 14 18
Osmolarity (mOsm/L) 750 750 750
*Provided as: Sodium Acetate, Potassium Chloride, Sodium Glycero-phosphate, Magnesium Sulfate, and Calcium Chloride.
Learn how the Kabiven portfolio helps enhance PN safety
References: 1. KABIVEN Prescribing Information, Fresenius Kabi LLC, USA, 2014. 2. PERIKABIVEN Prescribing Information, Fresenius Kabi LLC, USA, 2014. 3. Ayers P, Holcombe B, Plogsted S, Guenter P. eds. A.S.P.E.N. Parenteral Nutrition Handbook. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2014:123. 4. Mirtallo J, Patel M. Overview of parenteral nutrition. In: Mueller CM, ed. The A.S.P.E.N. Adult Nutrition Support Core Curriculum. 2nd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2012:234-244. 5. Data on file. Fresenius Kabi USA, LLC. March 2014.

Kabiven and Perikabiven three-chamber bags must be mixed prior to infusion. For admixing instructions see INSTRUCTIONS FOR USE in the prescribing information.

INDICATIONS AND LIMITATIONS OF USE

  • Kabiven and Perikabiven are each indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Kabiven and Perikabiven may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
  • Kabiven is indicated for intravenous infusion into a central vein.
  • Perikabiven is indicated for intravenous infusion into a peripheral or central vein.
  • Neither Kabiven nor Perikabiven is recommended for use in pediatric patients < 2 years, including preterm infants because the fixed content of the formulations do not meet the nutritional requirements in this age group.

IMPORTANT SAFETY INFORMATION

WARNING
  • Deaths in preterm infants have been reported in literature.
  • Autopsy findings included intravascular fat accumulation in the lungs.
  • Preterm and low birth weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

CONTRAINDICATIONS

  • Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients.
  • Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides >1000 mg/dL.
  • Inborn errors of amino acid metabolism.
  • Cardiopulmonary instability.
  • Hemophagocytic syndrome.

WARNINGS AND PRECAUTIONS

  • Kabiven is hypertonic and may cause vein irritation, vein damage and even thrombosis if infused in a peripheral vein. Only infuse Kabiven into a central vein.
  • Monitor for signs or symptoms of hypersensitivity reactions and discontinue infusion if reactions occur.
  • Monitor patient closely for signs and symptoms of infection, hypertriglyceridemia, hyperglycemia and refeeding complications.
  • Monitor laboratory parameters for alterations in electrolytes, liver and renal impairment, fluid status and coagulation parameters. Adjust rate and dose of Kabiven and Perikabiven according to clinical status.

To report suspected adverse reactions, contact Fresenius Kabi USA, LLC, at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Boxed Warning, for Kabiven and Perikabiven.